Drug intelligence / Profile preview

dexmedetomidine + ropivacaine + lidocaine + adrenaline

Development stage
Unknown
Lead developer
Orion Pharma
Modality
Small Molecules
Administration
Perineural, Epidural, Infiltration, Intrathecal
01

Overview

This is a combination of four agents commonly used in regional anesthesia and nerve blocks: - **Dexmedetomidine** is a highly selective α2-adrenergic receptor agonist with sedative, analgesic, and sympatholytic properties. It acts by inhibiting norepinephrine release both centrally (in the locus coeruleus) and peripherally, leading to sedation, analgesia, and reduced sympathetic tone. - **Ropivacaine** is a long-acting amide-type local anesthetic that blocks voltage-gated sodium channels on neuronal membranes, preventing nerve impulse conduction. - **Lidocaine** is an intermediate-duration amide-type local anesthetic that also inhibits voltage-gated sodium channels to block nerve conduction. - **Adrenaline (epinephrine)** is a non-selective adrenergic agonist added to local anesthetics for its vasoconstrictive effects; it reduces systemic absorption of the anesthetics at the injection site, prolonging their action and reducing toxicity. The combination of dexmedetomidine with ropivacaine-lidocaine-adrenaline has been shown in clinical studies to: - Prolong the duration of sensory and motor blockade - Improve postoperative analgesia - Shorten onset time for motor block without significant increases in adverse effects compared to standard regimens[2][6]. Dexmedetomidine enhances the effect primarily through peripheral α2-adrenoceptor-mediated mechanisms as well as central actions when absorbed systemically[6]. Adrenaline further prolongs anesthesia by vasoconstriction. This multi-agent mixture is used mainly for regional anesthesia such as brachial plexus blocks or other peripheral nerve blocks during surgery[2][6].

02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)ADRA2A (α2A)

Beyond the preview

Go deeper on dexmedetomidine + ropivacaine + lidocaine + adrenaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + ropivacaine + lidocaine + adrenaline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call